Conference abstractPublished 26 Sep 2016
Recent advancements and future opportunities for sustained ocular drug delivery systems
Novartis Institutes for Biomedical Research, Inc, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The field of sustained ocular drug delivey has seen remarkable innovations in the last decade. Many ocular blinding diseases require a chronic, in some cases lifelong treatment, and hence an unmet medical need for sustained ocular delivery technologies is becoming more evident. Recent advancements in novel drug delivery technologies have opened a new avenue in the field of sustained ophthalmic products. An integrative ocular drug delivery approach involvolving discovery scientists, pharmacologists, polymer chemists, clinicans, toxicologists and regulatory agenices is a paramount to the success of the sustained ocular delivery system. This talk will focus on key barriers and factors affecting ocular drug delivery, and strategies to overcome these barriers. Various routes of ocular drug administration and challenges associated with current strategies will be discussed in details. Key pharmacokinetic princiles and pharmacological considerations for developing successful sustained ocular delivery products will be presented. Recent advancements and future opportunities and a few success stories in the field of sustained drug delivery to the eye will also be discussed.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Viral Kansara”
